The silence has frustrated people who are keen not to have to wait until the autumn to get another dose of Covid vaccine.March 16, 2023Check out STAT+Sponsored By Jacob King/WPA Pool via Getty Images FDA offers radio silence on question of spring Covid boosters, as other countries push ahead The silence has frustrated people who are keen not to have to wait until the autumn to get another dose of Covid vaccine. By Helen Branswell STAT+ | Momentum grows to subject medical devices to medicine's gold standard — the placebo treatment In the medical device field, there is a fierce debate over whether clinical trials should include placebos to test for efficacy. By Lizzy Lawrence Large network of clinics offering ketamine for depression shuts down Ketamine Wellness Centers operated in nine states, using the anesthetic as a treatment for depression, chronic pain, and other conditions. By Isabella Cueto Adobe STAT+ | CRISPR? Nah. A new startup bets on an old approach to gene editing German researchers, having engineered recombinases to manipulate human DNA, are launching Seamless Therapeutics. By Jason Mast STAT+ | The big-money Medicare policy that has hospitals worried this Congress As debate in the Capitol rages about the future of the Medicare program, lawmakers could weigh so-called site-neutral payments. By Rachel Cohrs STAT+ | Califf criticizes insurers for doing too little on drug research The FDA chief wants insurers to help with drug research. It's a new request for an old initiative to find new ways to test drugs. By John Wilkerson Listen: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina STAT's Bob Herman joins us to explain how treatment algorithms powered by AI are being used by Medicare Advantage plans to deny claims. By Damian Garde and Meg Tirrell and Adam Feuerstein 'That is my dream': Scientist who uncovered likely leading cause of MS wants to tackle ALS next Alberto Ascherio's discovery of the likely leading cause of multiple sclerosis adds to research on the viral roots of chronic diseases. By Isabella Cueto STAT+ | Here's why there aren't many cheap, generic versions of pricey inhalers Researchers say a law designed to encourage generic drug development failed to foster competition for inhalers to treat asthma and COPD. By Ed Silverman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments